)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vista Pharmaceuticals
Vista Pharmaceuticals (524711) investor relations material
Vista Pharmaceuticals Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary14 Aug, 2026
Executive summary
Unaudited financial results for the quarter ended June 30, 2026, were approved by the board on August 14, 2026.
The company reported a net loss for the quarter, continuing a multi-year trend of losses.
Financial highlights
Revenue from operations for the quarter was Nil, compared to ₹151.88 lakhs in the same quarter last year.
Loss before tax for the quarter was ₹(132.71) lakhs, versus ₹(148.01) lakhs year-over-year.
Net loss after tax stood at ₹(98.59) lakhs, compared to ₹(129.04) lakhs in the prior year quarter.
Basic and diluted EPS for the quarter were both ₹(0.16), unchanged due to anti-dilutive effect of outstanding warrants.
Current liabilities exceeded current assets by ₹183.32 lakhs as of June 30, 2026.
Outlook and guidance
Management is negotiating debt restructuring and implementing cost rationalization.
A formal financial undertaking from warrant subscribers is expected to provide ₹922.49 lakhs to support operations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vista Pharmaceuticals
- FY98 losses narrowed, but accumulated losses and approval-related uncertainties remained substantial.524711
Q4 97/98 - Export growth strengthened, but reported losses and financing risks remained significant.524711Q4 98/99
- Exports grew, but financing costs and accounting changes deepened the loss.524711Q4 99/00
- Exports fell as losses deepened, while heavy interest and uninstalled plant constrained recovery.524711Q4 01/02
- Higher exports could not offset heavy finance costs and mounting losses.524711Q4 02/03
- Working-capital strain and debt defaults overshadowed a Rs. 180 lakh sales outlook.524711Q4 03/04
- A Rs 3.38 crore loss and Rs 1,991.66 lakh IDBI default drove a proposed funding issue.524711Q4 04/05
- FY06 profit hinged on exceptional IDBI waivers as debt settlement and facility upgrades reset operations.524711Q4 05/06
- FY07 loss widened as expansion progressed toward US generic production.524711Q4 06/07
- Loss widened as expansion spending advanced and Bactrim Generic awaited US FDA approval.524711Q4 07/08
Next Vista Pharmaceuticals earnings date
Q2 26/2719 Nov, 2026
Vista Pharmaceuticals
Next Vista Pharmaceuticals earnings date
Q2 26/2719 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vista Pharmaceuticals Limited is a pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical formulations. The company produces a variety of dosage forms including tablets, capsules, and liquids, catering to different therapeutic segments. It serves both domestic and international markets and may also operate as a contract manufacturer for other pharmaceutical companies. Vista Pharmaceuticals Limited focuses on regulatory compliance and quality standards in its production processes. The company is headquartered in Hyderabad, India, and its shares are listed on the BSE.